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A B S T R A C T
Purpose
To update key recommendations of the American Society of Clinical Oncology/College of
American Pathologists human epidermal growth factor receptor 2 (HER2) testing in breast cancer
guideline.
Methods
Based on the signals approach, an Expert Panel reviewed published literature and research survey
results on the observed frequency of less common in situ hybridization (ISH) patterns to update the
recommendations.
Recommendations
Two recommendations addressed via correspondence in 2015 are included. First, immunohisto-
chemistry (IHC) 2+ is deﬁned as invasive breast cancer with weak tomoderate completemembrane
staining observed in . 10% of tumor cells. Second, if the initial HER2 test result in a core needle
biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not “must”) be
ordered on the excision specimen based on speciﬁc clinical criteria. The HER2 testing algorithm for
breast cancer is updated to address the recommended work-up for less common clinical scenarios
(approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are
described as ISH group 2 (HER2/chromosome enumeration probe 17 [CEP17] ratio $ 2.0; average
HER2 copy number, 4.0 signals per cell), ISH group 3 (HER2/CEP17 ratio, 2.0; averageHER2 copy
number $ 6.0 signals per cell), and ISH group 4 (HER2/CEP17 ratio , 2.0; average HER2 copy
number $ 4.0 and , 6.0 signals per cell). The diagnostic approach includes more rigorous in-
terpretation criteria for ISH and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to
arrive at the most accurate HER2 status designation (positive or negative) based on combined
interpretation of the ISH and IHC assays. The Expert Panel recommends that laboratories using
single-probe ISH assays include concomitant IHC review as part of the interpretation of all single-
probe ISH assay results.
Find additional information at www.asco.org/breast-cancer-guidelines.
J Clin Oncol 36:2105-2122. © 2018 by American Society of Clinical Oncology and College of
American Pathologists
INTRODUCTION
First released in 2007 and updated in 2013, the
recommendations by the American Society of
Clinical Oncology (ASCO)/College of American
Pathologists (CAP) human epidermal growth
factor receptor 2 (HER2) testing Expert Panel are
aimed at improving the analytic validity of HER2
testing and the clinical utility of HER2 as a pre-
dictive biomarker for potential responsiveness to
therapies targeting the HER2 protein.1-4 Activating
mutations of the tyrosine kinase and extracellular
domains of HER2 in the absence of ampliﬁca-
tion or overexpression offer an alternative and
much less commonmechanism forHER2-targeted
therapy that is being explored in clinical trials of
small molecule kinase inhibitors.5 Data from
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THE BOTTOM LINE
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/
College of American Pathologists Clinical Practice Guideline Focused Update
Guideline Questions
What is the most appropriate deﬁnition for immunohistochemistry (IHC) 2+ (IHC equivocal)? Must human epidermal growth factor
receptor 2 (HER2) testing be repeated on a surgical specimen if initially negative test on core biopsy? What is the optimal algorithm for
less common patterns observed when performing dual-probe in situ hybridization (ISH) testing in breast cancer?
Target Population
Patients with breast cancer.
Target Audience
Medical oncologists, pathologists, surgeons, and radiation oncologists.
Methods
An Expert Panel was convened to develop updated clinical practice guideline recommendations based on a systematic review of the
medical literature.
Focused Update Recommendations
1. In the revised Figure 1, the revised deﬁnition of IHC 2+ (equivocal) is invasive breast cancer with “weak to moderate
complete membrane staining observed in . 10% of tumor cells.”
2. In the revised Table 2, it is now stated that, on the basis of some criteria (including a tumor grade 3), “If the initial HER2
test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 testmay be ordered on the
excision specimen . . . ”
3. If a case has a HER2/chromosome enumeration probe 17 (CEP17) ratio of$ 2.0 but the average HER2 signals per cell is
, 4.0, a deﬁnitive diagnosis will be rendered based on additional work-up. If not already assessed by the institution or
laboratory performing the ISH test, IHC testing for HER2 should be performed using sections from the same tissue
sample used for ISH and the slides from both ISH and IHC should be reviewed together to guide the selection of areas to
score by ISH (local practice considerations will dictate the best procedure to accomplish this concomitant review):
a. If the IHC result is 3+, diagnosis is HER2 positive.
b. If the IHC result is 2+, recount ISH by having an additional observer, blinded to previous ISH results, count at least 20
cells that include the area of invasive cancer with IHC 2+ staining:
• If reviewing the count by the additional observer changes the result into another ISH category, the result should be
adjudicated per internal procedures to deﬁne the ﬁnal category.
• If the count remains an average of , 4.0 HER2 signals per cell and the HER2/CEP17 ratio is $ 2.0, diagnosis is
HER2 negative with a comment. (Please note: Refer to text for speciﬁc comments about recommendations listed
as 3b, 3c, 4c, 5b, and 5c).
c. If the IHC result is 0 or 1+, diagnosis is HER2 negative with a comment. (Please note: Refer to text for speciﬁc
comments about recommendations listed as 3b, 3c, 4c, 5b, and 5c).
4. If a case has an average of $ 6.0 HER2 signals per cell with a HER2/CEP17 ratio of , 2.0, formerly diagnosed as ISH
positive for HER2, a deﬁnitive diagnosis will be rendered based on additional work-up. If not already assessed by the
institution or laboratory performing the ISH test, IHC testing for HER2 should be performed using sections from the
same tissue sample used for ISH and the slides from both ISH and IHC should be reviewed together to guide the selection
of areas to score by ISH (local practice considerations will dictate the best procedure to accomplish this concomitant
review):
a. If the IHC result is 3+, diagnosis is HER2 positive.
b. If the IHC result is 2+, recount ISH by having an additional observer, blinded to previous ISH results, count at least 20
cells that include the area of invasion with IHC 2+ staining:
(continued on following page)
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NRG trial B-47 (ClinicalTrials.gov identiﬁer: NCT01275677)
conﬁrmed the lack of beneﬁt from adjuvant trastuzumab for
patients whose tumors lack gene ampliﬁcation and are immu-
nohistochemistry (IHC) 1+ or 2+.6 Consequently, HER2 gene
ampliﬁcation assessed by in situ hybridization (ISH) or protein
overexpression assessed by IHC remains the primary predictor of
responsiveness to HER2-targeted therapies in breast cancer.
Greater communication among health care providers (espe-
cially pathologists and oncologists) and appropriate infrastructure
support for specimen handling and laboratory facilities led to
observed improvements in the analytic performance and accuracy
of HER2 testing.7 Greater clinical experience with the efﬁcacy and
safety of HER2-targeted therapies, and a meaningful reduction in
the high frequency of false-positive HER2 test results previously
observed,8 led the 2013 Expert Panel to provide additional
guidance regarding less common clinical scenarios to allow greater
discrimination between positive and negative results.1,4
Since 2013, several laboratory and clinical investigators have
reported on the practical implications of the 2013 Guideline
Update and the observed frequency of equivocal cases.9-13 These
reports have allowed the Expert Panel to evaluate the observed
frequency of less common HER2 testing patterns, their apparent
prognostic and predictive value when retrospectively analyzed
within clinical trial data sets, and the critical need to understand
the underlying distribution of HER2 IHC test results in cases that
are submitted for additional testing (eg, by ISH) by a reference
laboratory. The Expert Panel wished to clarify one of its 2013
recommendations that led some laboratories to adopt the use of
THE BOTTOM LINE (CONTINUED)
• If reviewing the count by the additional observer changes the result into another ISH category, the result should be
adjudicated per internal procedures to deﬁne the ﬁnal category.
• If the HER2/CEP17 ratio remains , 2.0 with $ 6.0 HER2 signals per cell, diagnosis is HER2 positive.
c. If the IHC result is 0 or 1+, diagnosis is HER2 negative with a comment. (Please note: Refer to text for speciﬁc
comments about recommendations listed as 3b, 3c, 4c, 5b, and 5c).
5. If the case has an average HER2 signals per tumor cell of $ 4.0 and , 6.0 and the HER2/CEP17 ratio is , 2.0, formerly
diagnosed as ISH equivocal for HER2, a deﬁnitive diagnosis will be rendered based on additional work-up. If not already
assessed by the institution or laboratory performing the ISH test, IHC testing for HER2 should be performed using
sections from the same tissue sample used for ISH and the slides from both ISH and IHC should be reviewed together to
guide the selection of areas to score by ISH (local practice considerations will dictate the best procedure to accomplish this
concomitant review):
a. If the IHC result is 3+, diagnosis is HER2 positive.
b. If the IHC result is 2+, recount ISH by having an additional observer, blinded to previous ISH results, count at least 20
cells that include the area of invasion with IHC 2+ staining:
• If reviewing the count by the additional observer changes the result into another ISH category, the result should be
adjudicated per internal procedures to deﬁne the ﬁnal category.
• If the count remains an average of $ 4.0 and , 6.0 HER2 signals per cell with a HER2/CEP17 ratio of , 2.0,
diagnosis is HER2 negative with a comment. (Please note: Refer to text for speciﬁc comments about
recommendations listed as 3b, 3c, 4c, 5b, and 5c).
c. If the IHC result is 0 or 1+, diagnosis is HER2 negative with a comment. (Please note: Refer to text for speciﬁc
comments about recommendations listed as 3b, 3c, 4c, 5b, and 5c).
Note: In Figure 2, a new footnote states that the Expert Panel recommends that concomitant IHC review become part of the
interpretation of single-probe ISH results and that the Expert Panel preferentially recommends the use of dual-probe instead of single-
probe ISH assays.
Refer to Table 1 for the full list of recommendations.
Additional Resources
More information, including a Data Supplement with additional evidence tables, a Methodology Supplement with information about
evidence quality and strength of recommendations, slide sets, and clinical tools and resources, is available at www.asco.org/breast-
cancer-guidelines. Patient information is available at www.cancer.net
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients
should have the opportunity to participate.
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Table 1. Summary of All Recommendations (original recommendations and focused update recommendations)
Topic 2013 Recommendations 2018 Focused Update Recommendations
Specimens to be tested All newly diagnosed patients with breast cancer must have
a HER2 test performed. Patients who then develop
metastatic disease must have a HER2 test performed in
a metastatic site, if tissue sample is available.
No change.
Optimal algorithm for
HER2 testing
Must report HER2 test result as positive for HER2 if:
IHC 3+ based on circumferential membrane staining that is
complete, intense
ISH positive based on:
Single-probe average HER2 copy number $ 6.0 signals/
cell
Dual-probe HER2/CEP17 ratio of $ 2.0; with an average
HER2 copy number $ 4.0 signals/cell
Dual-probe HER2/CEP17 ratio of $ 2.0; with an average
HER2 copy number , 4.0;
Dual-probe HER2/CEP17 ratio of , 2.0 with an average
HER2 copy number $ 6.0 signals/cell
1. In the revised Figure 1, the revised deﬁnition of IHC 2+
(equivocal) is invasive breast cancer with “weak to moderate
complete membrane staining observed in . 10% of tumor
cells.”
2. In the revised Table 2, it is now stated that, on the basis of
some criteria (including a tumor grade 3), “If the initial HER2
test result in a core needle biopsy specimen of a primary
breast cancer is negative, a new HER2 test may be ordered
on the excision specimen . . .”
3. If a case has a HER2/CEP17 ratio of $ 2.0 but the average
HER2 signals/cell is , 4.0, a deﬁnitive diagnosis will be
rendered based on additional work-up. If not already
assessed by the institution or laboratory performing the ISH
test, IHC testing for HER2 should be performed using
sections from the same tissue sample used for ISH, and the
slides from both ISH and IHC should be reviewed together to
guide the selection of areas to score by ISH (local practice
considerations will dictate the best procedure to accomplish
this concomitant assessment):
a. If the IHC result is 3+, diagnosis is HER2 positive
b. If the IHC result is 2+, recount ISH by having an
additional observer, blinded to previous ISH results, count at
least 20 cells that include the area of invasive cancer with IHC
2+ staining:
If reviewing the count by the additional observer
changes the result into another ISH category, the result
should be adjudicated per internal procedures to deﬁne the
ﬁnal category.
If the count remains an average of , 4.0 HER2 signals/
cell and the HER2/CEP17 ratio is $ 2.0, diagnosis is HER2
negative with a comment*
c. If the IHC result is 0 or 1+, diagnosis is HER2 negative
with a comment.*
4. If a case has an average of $ 6.0 HER2 signals/cell with
a HER2/CEP17 ratio of , 2.0, formerly diagnosed as ISH
positive for HER2, a deﬁnitive diagnosis will be rendered
based on additional work-up. If not already assessed by the
institution or laboratory performing the ISH test, IHC testing
for HER2 should be performed using sections from the same
tissue sample used for ISH, and the slides from both ISH and
IHC should be reviewed together to guide the selection of
areas to score by ISH (local practice considerations will
dictate the best procedure to accomplish this concomitant
review):
a. If the IHC result is 3+, diagnosis is HER2 positive
b. If the IHC result is 2+, recount ISH by having an
additional observer, blinded to previous ISH results, count at
least 20 cells that include the area of invasion with IHC 2+
staining:
If reviewing the count by the additional observer
changes the result into another ISH category, the result
should be adjudicated per internal procedures to deﬁne the
ﬁnal category
If the HER2/CEP17 ratio remains, 2.0 with$ 6.0 HER2
signals/cell, diagnosis is HER2 positive
c. If the IHC result is 0 or 1+, diagnosis is HER2 negative
with a comment*
5. If the case has an average HER2 signals/tumor cell of $ 4.0
and , 6.0 and the HER2/CEP17 ratio is , 2.0, formerly
diagnosed as ISH equivocal for HER2, a deﬁnitive diagnosis
will be rendered based on additional work-up. If not already
assessed by the institution or laboratory performing the ISH
test, IHC testing for HER2 should be performed using
sections from the same tissue sample used for ISH, and the
slides from both ISH and IHC should be reviewed together to
guide the selection of areas to score by ISH (local practice
considerations will dictate the best procedure to accomplish
this concomitant review):
a. If the IHC result is 3+, diagnosis is HER2 positive
b. If the IHC result is 2+, recount ISH by having an additional
observer, blinded to previous ISH results, count at least 20 cells
that include the area of invasion with IHC 2+ staining:
Must report HER2 test result as equivocal and order reﬂex
test (same specimen using the alternative test) or new test
(new specimen, if available, using same or alternative test)
if:
IHC 2+ based on circumferential membrane staining that
is incomplete and/or weak to moderate and within . 10%
of the invasive tumor cells or complete and circumferential
membrane staining that is intense and within# 10% of the
invasive tumor cells
ISH equivocal based on:
Single-probe ISH average HER2 copy number $ 4.0
and # 6.0 signals/cell
Dual-probeHER2/CEP17 ratio of, 2.0with an average
HER2 copy number $ 4.0 and # 6.0 signals/cell
Must report HER2 test result as negative if a single test (or
both tests) performed show:
IHC 1+ as deﬁned by incomplete membrane staining
that is faint or barely perceptible and within . 10% of the
invasive tumor cells
IHC 0 as deﬁned by no staining observed or membrane
staining that is incomplete and is faint or barely perceptible
and within # 10% of the invasive tumor cells
ISH negative based on:
Single-probe average HER2 copy number , 4.0
signals/cell
Dual-probeHER2/CEP17 ratio of, 2.0with an average
HER2 copy number of 4.0 signals/cell
Must report HER2 test result as indeterminate if technical
issues prevent one or both tests (IHC and ISH) from being
reported as positive, negative, or equivocal. Conditions
may include:
Inadequate specimen handling
Artifacts (crush or edge artifacts) that make
interpretation difﬁcult
Analytic testing failure
Another specimen should be requested for testing to
determine HER2 status.
Reason for indeterminate testing should be noted in
a comment in the report.
(continued on following page)
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Table 1. Summary of All Recommendations (original recommendations and focused update recommendations) (continued)
Topic 2013 Recommendations 2018 Focused Update Recommendations
If reviewing the count by the additional observer changes
the result into another ISH category, the result should be
adjudicated per internal procedures to deﬁne the ﬁnal category
If the count remains an average of$ 4.0 and, 6.0 HER2
signals/cell with a HER2/CEP17 ratio of , 2.0, diagnosis is
HER2 negative with a comment*
c. If the IHC result is 0 or 1+, diagnosis is HER2 negative
with a comment*
ISH rejection criteria Test is rejected and repeated if:
Controls are not as expected
Observer cannot ﬁnd and count at least two areas of
invasive tumor
. 25% of signals are unscorable due to weak signals
. 10% of signals occur over cytoplasm
Nuclear resolution is poor
Autoﬂuorescence is strong
Report HER2 test result as Indeterminate as per
parameters described.
No change
ISH interpretation The pathologist should scan the entire ISH slide before counting
at least 20 cells or use IHC to deﬁne the areas of potential
HER2 ampliﬁcation.
If there is a second population of cells with increased HER2
signals/cell and this cell population consists of . 10% of
tumor cells on the slide (deﬁned by image analysis or visual
estimation of the ISH or IHC slide), a separate counting of at
least 20 nonoverlapping cells must also be performed within
this cell population and reported.
For brightﬁeld ISH, counting requires comparison between
patterns in normal breast and tumor cells because artifactual
patterns may be seen that are difﬁcult to interpret. If tumor
cell pattern is neither normal nor clearly ampliﬁed, test should
be submitted for expert opinion.
The pathologist should scan the entire ISH slide before counting
at least 20 cells or use IHC to deﬁne the areas of potential
HER2 ampliﬁcation.
If there is a second population of contiguous cells with
increased HER2 signals/cell and this cell population consists
of . 10% of tumor cells on the slide (deﬁned by image
analysis or visual estimation of the ISH or IHC slide),
a separate counting of at least 20 nonoverlapping cells must
also be performed within this cell population and reported.
Acceptable (IHC and
ISH) tests
Should preferentially use an FDA-approved IHC, brightﬁeld ISH,
or FISH assay.
No change
IHC rejection criteria Test is rejected and repeated or tested by FISH if:
Controls are not as expected
Artifacts involve most of sample
Sample has strong membrane staining of normal breast
ducts (internal controls)
No change
IHC interpretation
criteria
Should interpret IHC test using a threshold of . 10% of tumor
cells that must show homogeneous, dark circumferential
(chicken wire) pattern to call result 3+, HER2 positive.
No change
Reporting
requirements for all
assay types
Report must include guideline-detailed elements except for
changes to reporting requirement and algorithms deﬁned in
this table.
No change
Optimal tissue handling
requirements
Time from tissue acquisition to ﬁxation should be as short as
possible; samples for HER2 testing are ﬁxed in 10% neutral
buffered formalin for 6-72 hours; cytology specimens must
be ﬁxed in formalin.
Samples should be sliced at 5- to 10-mm intervals after
appropriate gross inspection and margin designation and
placed in a sufﬁcient volume of neutral buffered formalin.
No change
Any exceptions to this processmust be included in the report.
Optimal tissue
sectioning
requirements
Sections should ideally not be used for HER2 testing if cut . 6
weeks earlier; this may vary with primary ﬁxation or storage
conditions
No change
Optimal internal
validation procedure
Validation of test must be performed before test is offered No change
Optimal initial test
validation
Laboratories performing these tests should be following all
accreditation requirements, one of which is initial testing
validation. The laboratory should ensure that initial validation
conforms to the published 2010 ASCO/CAP
recommendations for IHC testing of ER and PgR guideline
validation requirements with 20 negative and 20 positive for
FDA-approved assays and 40 negative and 40 positive for
LDTs. This requirement does not apply to assays that were
previously validated in conformance with the 2007 ASCO/
CAP HER2 testing guideline, and those who routinely
participate in external proﬁciency testing for HER2 tests,
such as the program offered by CAP.
No change
(continued on following page)
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multiple alternative chromosome 17 probe testing as the sole strategy
to resolve equivocal HER2 test results by ISH, despite limited evidence
on analytical and clinical validity. The full set of recommendations
from 2013 and 2018, highlighting changes, is available in Table 1.
The HER2 testing Expert Panel has identiﬁed ﬁve clinical
questions that form the core of this Focused Update. Two of them
(Clinical Questions 1 and 2) were addressed in a previous correspon-
dence by the Expert Panel published in Journal of Clinical Oncology
(JCO) in 201514 and are included here in the formof Figure 1 (algorithm
for IHC testing), and Table 2 (histopathologic features suggestive of
possible test discordance), both revised from the 2013 guideline. Figure 2
is an algorithm for single-probe ISH testing and includes a new footnote
with a recommendation that concomitant IHC review become part of
the interpretation of single-probe ISH results. Clinical Questions 3, 4,
and 5 address less common patterns observed when performing dual-
probe ISH testing10,12 and are graphically summarized in Figures 3 to 6
(algorithm for dual-probe ISH testing), also revised.
A new Table 3 describes the patterns of HER2 ISH testing
using a dual-probe assay and lists the clear effect of the underlying
distribution of HER2 IHC test results on the frequency of less
common patterns of ISH (hereafter called groups 2, 3, and 4).10,12
In the population at large, approximately 95% of tumors tested for
HER2 by dual-probe ISH will consist of group 1 (HER2 positive)
and group 5 (HER2 negative). It is expected that approximately 5%
of cases tested by ISH will fall into groups 2, 3, or 4, and available
clinical outcome data from related clinical trials, albeit of limited
statistical power, have allowed the Expert Panel to more carefully
deﬁne the expected prognostic and predictive behavior of these cases.
Most important, after careful consideration of the available
evidence and expert opinions, the Expert Panel revised the diagnostic
approach to groups 2 to 4 to include more rigorous interpretation
criteria for dual-probe ISH testing and to require concomitant IHC
review, to arrive at the most accurate HER2 status designation
(positive or negative) based on the combined interpretation of the
ISH and IHC assays. The Expert Panel recommends that such
concomitant review be performed in the same institution to ensure
parallel interpretation and quality of the two assays.
While the main focus was to clarify the less common test
results observed with the two-probe ISH assays, the recommen-
dations affect the users of single-probe ISH assays. Therefore, the
Expert Panel now recommends that concomitant IHC review be-
come part of the interpretation of single-probe ISH results, to allow
the most accurate HER2 designation (Fig 2). The Expert Panel also
preferentially recommends the use of dual-probe instead of single-
probe ISH assays, while it recognizes that several single-probe ISH
assays have regulatory approval in many parts of the world.
GUIDELINE QUESTIONS
This Focused Update addresses ﬁve clinical questions raised after
the publication of the 2013 Guideline Update:
Table 1. Summary of All Recommendations (original recommendations and focused update recommendations) (continued)
Topic 2013 Recommendations 2018 Focused Update Recommendations
Optimal initial test
validation
Laboratories are responsible for ensuring the reliability and
accuracy of their testing results, by compliance with
accreditation and proﬁciency testing requirements for HER2
testing assays. Speciﬁc concordance requirements are not
required.
No change
Optimal monitoring of
test concordance
between methods
See text following under Optimal Laboratory Accreditation No change
Optimal internal QA
procedures
Should review and document external and internal controls with
each test and each batch of tests.
Ongoing quality control and equipment maintenance
Initial and ongoing laboratory personnel training and
competency assessment
Use of standardized operating procedures including routine
use of control materials
Revalidation of procedure if changed
Ongoing competency assessment and documentation of
the actions taken as a part of the laboratory record.
No change
Optimal external
proﬁciency
assessment
Participation in and successful completion of external
proﬁciency testing program with at least two testing events
(mailings) a year
Satisfactory performance requires at least 90% correct
responses on graded challenges for either test
Unsatisfactory performance will require laboratory to
respond according to accreditation agency program
requirements
No change
Optimal laboratory
accreditation
Onsite inspection every other year with annual requirement for
self-inspection
Reviews laboratory validation, procedures, QA results and
processes, results, and reports
Unsatisfactory performance results in suspension of
laboratory testing for HER2 for that method
No change
Abbreviations: CAP, College of American Pathologists; CEP17, chromosome enumeration probe 17; ER, estrogen receptor; FDA, US Food and Drug Administration;
FISH, ﬂuorescent in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; LDT, laboratory-
developed test; PgR, progesterone receptor; QA, quality assurance.
*Refer to text for the speciﬁc comments associated with each recommendation.
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Clinical Question 1
What is the most appropriate deﬁnition for IHC 2+ (IHC
equivocal)?
Clinical Question 2
Must HER2 testing be repeated on a surgical specimen if
initially negative test on core biopsy?
Clinical Question 3
Should invasive cancers with a HER2/chromosome enu-
meration probe 17 (CEP17) ratio of $ 2.0 but an average HER2
copy number of , 4.0 signals per cell be considered ISH positive?
Clinical Question 4
Should invasive cancers with an average HER2 copy number
of $ 6.0 signals per cell but a HER2/CEP17 ratio of , 2.0 be
considered ISH positive?
Clinical Question 5
What is the appropriate diagnostic work-up for invasive
cancers with an average HER2 copy number of $ 4.0 but , 6.0
signals per cell and a HER2/CEP17 ratio of , 2.0 and initially
deemed to have an equivocal HER2 ISH test result?
Clinical Questions 1 and 2 were formally addressed in
a correspondence from the ASCO/CAP HER2 testing Expert Panel
published in JCO in 201514 in response to a correspondence by
Rakha et al,17 and this Focused Update contains a revised
Figure 1 (Clinical Question 1) and a revised Table 2 (Clinical
Question 2).
Clinical Questions 3, 4, and 5 regarding dual-probe (dual-
signal) ISH testing (Figs 3 to 6) were addressed by the Expert Panel
in a meeting at ASCO headquarters on November 28 and 29, 2016,
and in subsequent conference calls and electronic communica-
tions. Figure 2 (single-probe ISH) from the 2013 Guideline Update
includes a new footnote with a recommendation that concomitant
IHC review should become part of the interpretation of single-
probe ISH results. Table 1 contains a summary of the recom-
mendations of the 2013 Guideline Update and the 2018 Focused
Update. Figure 7, describing the number of laboratories partici-
pating in predictive marker proﬁciency testing for HER2, has been
updated.
METHODS
Guideline Update Process
This systematic review-based guideline product was developed by
a multidisciplinary Expert Panel (Appendix Table A1, online only), which
included a patient representative and ASCO guidelines staff with health
research methodology expertise. PubMed and the Cochrane Library were
searched for randomized controlled trials, systematic reviews, meta-
analyses, and clinical practice guidelines for the period from January 1,
2013, through May 11, 2017. The disease and intervention search terms
HER2 testing (invasive component) by validated IHC assay
Batch controls and on-slide controls show appropriate staining
Circumferential membrane
staining that is complete,
intense, and in > 10% of
tumor cells*
Weak to moderate complete
membrane staining observed
in > 10% of tumor cells
Incomplete membrane staining
that is faint/barely perceptible
and in > 10% of tumor cells
No staining is observed
or
Membrane staining that is
incomplete and is faint/barely
perceptible and in ≤ 10% of
tumor cells
Must order reflex test (same specimen using ISH)
or order a new test
(new specimen if available, using IHC or ISH)
IHC 3+
positive
IHC 2+
equivocal
IHC 1+
negative
IHC 0
negative
Fig 1. Algorithm for evaluation of human epidermal growth factor receptor 2 (HER2) protein expression by immunohistochemistry (IHC) assay of the invasive component
of a breast cancer specimen. Note: The ﬁnal reported results assume that there is no apparent histopathologic discordance observed by the pathologist. Unusual staining
patterns of HER2 by IHC can be encountered that are not covered by these deﬁnitions. In practice, these patterns are rare and if encountered should be considered IHC 2+
equivocal. As one example, some speciﬁc subtypes of breast cancers can show IHC staining that is moderate to intense but incomplete (basolateral or lateral) and can be
found to be HER2 ampliﬁed. Another example is circumferential membrane IHC staining that is intense but in# 10% of tumor cells (heterogeneous, but limited in extent).
Such cases can be considered 2+ equivocal, but additional samples may reveal different percentages of HER2 positive staining. ISH, in situ hybridization. (*) Readily
appreciated using a low power objective and observed within a homogeneous and contiguous invasive cell population.
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were those that were used for the 2013 Guideline Update. The updated
search was guided by the signals18 approach that is designed to identify
only new, potentially practice-changing data (signals) that might
translate into revised practice recommendations. The approach relies on
targeted routine literature searching and the expertise of ASCO Expert
Panel members to help identify potential signals. Additional in-
formation about the literature search strategy string and results, as
well as a discussion of the ASCO signals approach to guideline
HER2 testing (invasive component) by validated
single-probe ISH assay
Batch controls and on-slide controls show
appropriate hybridization
Average HER2 copy number
≥ 6.0 signals/cell*
Average HER2 copy number
≥ 4.0 and < 6.0 signals/cell†
Average HER2 copy number
< 4.0 signals/cell*
Concurrent IHC 3+
and/or
concurrent dual-probe ISH
group 1‡
Concurrent IHC 0, 1+
and/or
concurrent dual-probe ISH
group 5‡
Concurrent IHC 2+
Perform dual−probe
ISH for final result‡
ISH
positive
ISH
negative
Fig 2. Algorithm for evaluation of human epidermal growth factor receptor 2 (HER2) gene ampliﬁcation by in situ hybridization (ISH) assay of the invasive component of
a breast cancer specimen using a single-signal (HER2 gene) assay (single-probe ISH). Note: The ﬁnal reported results assume that there is no apparent histopathologic
discordance observed by the pathologist. (*) It is recommended that concomitant immunohistochemistry (IHC) review become part of the interpretation of single-probe
ISH results. The Expert Panel also preferentially recommends the use of dual-probe instead of single-probe ISH assays. (†) Using sections from the same tissue samples
used for single-probe ISH, perform IHC (if not already performed) and/or dual-probe ISH. If IHC results are 2+ equivocal, it is recommended to also perform dual-probe ISH.
(‡) If initial assessment of dual-probe ISH is suggestive of groups 2, 3, or 4, follow the algorithm described in Figure 3.
Table 2. Histopathologic Features Suggestive of Possible HER2 Test Discordance
Criteria to Consider*
A new HER2 test should not be ordered if the following histopathologic ﬁndings occur and the initial HER2 test was negative:
Histologic grade 1 carcinoma of the following types:
Inﬁltrating ductal or lobular carcinoma, ER and PgR positive
Tubular (at least 90% pure)
Mucinous (at least 90% pure)
Cribriform (at least 90% pure)
Adenoid cystic carcinoma (90% pure) and often triple negative
Similarly, a new HER2 test should be ordered if the following histopathologic ﬁndings occur and the initial HER2 test was positive:
Histologic grade 1 carcinoma of the following types:
Inﬁltrating ductal or lobular carcinoma, ER and PgR positive
Tubular (at least 90% pure)
Mucinous (at least 90% pure)
Cribriform (at least 90% pure)
Adenoid cystic carcinoma (90% pure) and often triple negative
If the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 testmay be ordered on the excision specimen if one
of the following is observed:
Tumor is grade 3
Amount of invasive tumor in the core biopsy specimen is small
Resection specimen contains high-grade carcinoma that is morphologically distinct from that in the core
Core biopsy result is equivocal for HER2 after testing by both ISH and IHC
There is doubt about the handling of the core biopsy specimen (long ischemic time, short time in ﬁxative, different ﬁxative) or the test is suspected by the pathologist
to be negative on the basis of testing error
NOTE. Adapted from 2013 ASCO/CAP HER2 Testing Guideline.1
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; PgR, progesterone
receptor.
*Criteria to consider if there are concerns regarding discordance with apparent histopathologic ﬁndings and possible false-negative or false-positive HER2 test result.
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updating, are available at www.asco.org/breast-cancer-guidelines and
in the 2018 Data Supplement and 2018 Methodology Supplement, re-
spectively. A QUOROM diagram of the updated search and the clinical
questions are provided (Data Supplement). In addition to the literature
search, a research survey was distributed to gather additional real-
world data from laboratories from before and after implementation of
the ASCO/CAP HER2 Testing in Breast Cancer 2013 Update. Addi-
tional information regarding this survey process is available in the Data
Supplement.
The Expert Panel met during a 2-day in-person meeting in No-
vember 2016 to consider the evidence for each of the recommendations
contained in this 2018 Focused Update. Laboratories that shared with the
HER2 testing (invasive component) by validated dual-probe ISH assay
Batch controls and on-slide controls show appropriate hybridization
HER2/CEP17 ratio ≥ 2.0 HER2/CEP17 ratio < 2.0
Group 1
Average HER2 copy
number ≥ 4.0 signals/cell
Group 2
Average HER2 copy
number < 4.0 signals/cell
Group 3
Average HER2 copy
number ≥ 6.0 signals/cell
Group 4
Average HER2 copy
number ≥ 4.0 and < 6.0
signals/cell
Group 5
Average HER2 copy
number < 4.0 signals/cell
ISH
positive
ISH
negative
Additional work-up
required (see Fig 4)
Additional work-up
required (see Fig 5)
Additional work-up
required (see Fig 6)
Fig 3. Algorithm for evaluation of human epidermal growth factor receptor 2 (HER2) gene ampliﬁcation by in situ hybridization (ISH) assay of the invasive component of
a breast cancer specimen using a dual-signal (HER2 gene) assay (dual-probe ISH). Note: The ﬁnal reported results assume that there is no apparent histopathologic
discordance observed by the pathologist. Regarding groups 2, 3, and 4, if not already assessed by the institution or laboratory performing the ISH test, immunohis-
tochemistry (IHC) testing for HER2 should be performed using sections from the same tissue sample used for ISH, and the slides from both ISH and IHC should be
reviewed together to guide the selection of areas to score by ISH (local practice considerations will dictate the best procedure to accomplish this concomitant assessment).
CEP17, chromosome enumeration probe 17.
HER2/CEP17 ratio ≥ 2.0
Average HER2 signals/cell < 4.0
Assess IHC using sections from the
same tissue sample used for ISH
IHC 0 or 1+ IHC 2+ IHC 3+
HER2/CEP17 Ratio ≥ 2.0
Average HER2 signals/cell < 4.0
Other ISH
result
HER2 negative
with
comment*
Result should be
adjudicated per internal
procedures to determine
final category
Observer blinded to previous results
recounts ISH, counting at least 20 cells
HER2 positive
HER2 negative with
comment*
Fig 4. Clinical Question 3, group 2. (*) Evidence is
limited on the efﬁcacy of HER2-targeted therapy in the
small subset of cases with a HER2/CEP17 ratio $ 2.0
and an average HER2 copy number of , 4.0 per cell. In
the ﬁrst generation of adjuvant trastuzumab trials, pa-
tients in this subgroup who were randomly assigned to
the trastuzumab arm did not seem to derive an im-
provement in disease-free or overall survival, but there
were too few such cases to draw deﬁnitive conclusions.
IHC expression for HER2 should be used to complement
ISH and deﬁne HER2 status. If the IHC result is not 3+
positive, it is recommended that the specimen be
considered HER2 negative because of the low HER2
copy number by ISH and the lack of protein over-
expression. CEP17, chromosome enumeration probe
17; HER2, human epidermal growth factor receptor 2;
IHC, immunohistochemistry; ISH, in situ hybridization.
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Expert Panel their clinical experience with HER2 testing since the
publication of the 2013 Guideline Update participated in the open
session of the meeting. The guideline was circulated in draft form to the
Expert Panel. Draft recommendations were released to the public for an
open comment period between May 22 and June 19, 2017. ASCO’s
Clinical Practice Guidelines Committee reviewed and approved the ﬁnal
document. For CAP, an independent review panel was assembled to
review and approve the guideline. The independent review panel was
masked to the Expert Panel and was vetted through the conﬂict of interest
process.
HER2/CEP17 ratio < 2.0
Average HER2 signals/cell ≥ 6.0
Assess IHC using sections from the
same tissue sample used for ISH
IHC 0 or 1+ IHC 2+ IHC 3+
HER2/CEP17 ratio < 2.0
Average HER2 signals/cell ≥ 6.0
Other ISH
result
HER2
positive
Result should be
adjudicated per internal
procedures to determine
final category
Observer blinded to previous results
recounts ISH, counting at least 20 cells
HER2 positive
HER2 negative with
comment*
Fig 5. Clinical Question 4, group 3. (*) There are in-
sufﬁcient data on the efﬁcacy of HER2-targeted therapy
in cases with a HER2 ratio of , 2.0 in the absence of
protein overexpression because such patients were not
eligible for the ﬁrst generation of adjuvant trastuzumab
clinical trials. When concurrent IHC results are negative
(0 or 1+), it is recommended that the specimen be
considered HER2 negative. CEP17, chromosome enu-
meration probe 17; HER2, human epidermal growth
factor receptor 2; IHC, immunohistochemistry; ISH, in
situ hybridization.
HER2/CEP17 ratio < 2.0
Average HER2 signals/cell ≥ 4.0 and < 6.0
Assess IHC using sections from the
same tissue sample used for ISH
IHC 0 or 1+ IHC 2+ IHC 3+
HER2/CEP17 ratio < 2.0
Average HER2 signals/cell ≥ 4.0 and < 6.0
HER2 negative with
comment*
Other ISH
result
Result should be
adjudicated per internal
procedures to determine
final category
Observer blinded to previous results
recounts ISH, counting at least 20 cells
HER2 positive
HER2 negative with
comment*
Fig 6. Clinical Question 5, group 4. (*) It is uncertain
whether patients with an average of $ 4.0 and , 6.0
HER2 signals per cell and a HER2/CEP17 ratio of, 2.0
beneﬁt from HER2-targeted therapy in the absence of
protein overexpression (IHC 3+). If the specimen test
result is close to the ISH ratio threshold for positive,
there is a higher likelihood that repeat testingwill result
in different results by chance alone. Therefore, when
IHC results are not 3+ positive, it is recommended that
the sample be considered HER2 negative without
additional testing on the same specimen. CEP17,
chromosome enumeration probe 17; HER2, human
epidermal growth factor receptor 2; IHC, immunohis-
tochemistry; ISH, in situ hybridization.
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Only recommendations relating to the updated clinical questions
have changed. The Data Supplement provides clinical questions corre-
sponding to all recommendations from the 2013 Guideline Update.
This ASCO/CAP Clinical Practice Guideline Focused Update
provides select recommendations with a comprehensive discussion of the
relevant literature from January 1, 2013, to May 11, 2017, for
these speciﬁc recommendations. The full guideline, which this revision
applies to, and additional information are available at www.asco.org/
breast-cancer-guidelines. The complete list of recommendations,
including the updated recommendations, is in Table 1. All funding for
the administration of the project was provided by ASCO and CAP.
Guideline Disclaimer
The clinical practice guidelines and other guidance published herein
are provided by the American Society of Clinical Oncology, Inc. (“ASCO”)
to assist providers in clinical decision making. The information therein
should not be relied upon as being complete or accurate, nor should it be
considered as inclusive of all proper treatments or methods of care or as
a statement of the standard of care. With the rapid development of sci-
entiﬁc knowledge, new evidence may emerge between the time in-
formation is developed and when it is published or read. The information
is not continually updated and may not reﬂect the most recent evidence.
The information addresses only the topics speciﬁcally identiﬁed therein
and is not applicable to other interventions, diseases, or stages of
diseases. This information does not mandate any particular course of
medical care. Further, the information is not intended to substitute for
the independent professional judgment of the treating provider, as the
information does not account for individual variation among patients.
Recommendations reﬂect high, moderate or low conﬁdence that the
recommendation reﬂects the net effect of a given course of action. The
use of words like “must,” “must not,” “should,” and “should not” indicate
that a course of action is recommended or not recommended for either most
or many patients, but there is latitude for the treating physician to select
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Fig 7. Number of laboratories participating in
predictive marker proﬁciency testing for hu-
man epidermal growth factor receptor 2
(HER2) by immunohistochemistry (IHC), HER2
by ﬂuorescent in situ hybridization (FISH), and
estrogen receptor (ER) by IHC through the
College of American Pathologists Laboratory
Improvement Program.
Table 3. Distribution by Dual FISH and IHC Testing Results in Reported Data Sets
Initial Test Results
Laboratory
HERA Central
Laboratory15
BCIRG Central
Laboratory10
USC Breast Cancer
Analysis Laboratory12
Mayo Clinic
Cytogenetics
Laboratory11
UK NEQAS
2009-2016*
Stanford/
UCSF/
UWMC16
FISH distribution
n 6,018 10,468 7,526 2,851 11,116 8,068
Group 1 ratio $ 2.0; HER2 $ 4.0 55.0 ($ 6.0, 48.7;
$ 4.0-6.0, 6.3)
40.8 17.7 11.8 14.2 13.8
Group 2 ratio $ 2.0; HER2 , 4.0 0.8 0.7 0.4 1.3 3.7 1.4
Group 3 ratio , 2.0; HER2 $ 6.0 0.4 0.5 0.6 3.0 1.1 0.8
Group 4 ratio , 2.0; HER2 $ 4.0
, 6.0 (after alternative probe: pos,
equivocal, neg)
1.9 4.1 4.6 14.2 (7.5, 5.5, 1.3) 7.6 5.2
Group 5 ratio , 2.0; HER2 , 4.0 41.9 53.9 76.7 69.6 73.4 78.8
IHC distribution
n 3,089 4,331 7,526 1,922 11,116 3,027
0 IHC 0-1+, 2.0 54.5 51.7 2.4 0.5 IHC 0-1+, 38.1
1+ (including 0 or 1+) — 9.4 31.0 8.0 1.8 —
2+ (including (1+/2+ or 2+3+)† 61.8 13.7 9.0 87.1† 96.5† 2+, 46.6
3+ 36.2 22.4 8.4 2.5 1.3 3+, 15.3
NOTE. Data are presented as % unless otherwise indicated.
Abbreviations: BCIRG, Breast Cancer International Research Group; FISH, ﬂuorescent in situ hybridization; HERA, Herceptin Adjuvant trial; neg, negative; pos, positive;
UCSF, University of California, San Francisco; UK NEQAS, United Kingdom National External Quality Assessment Service; USC, University of Southern California;
UWMC, University of Washington Medical Center.
*Andrew Dodson, personal communication October 2016.
†IHC 1+ or 2+ and 2+ or 3+were grouped together with IHC 2+. In each column for a speciﬁc laboratory or study, the top set of percentages describes the distribution of
group 1 to 5 results when tested using a dual-probe FISH assay, while the bottom set of percentages describes the distribution of IHC tests results of the samples
submitted to that laboratory or study for dual-probe ISH testing and as described in each publication.
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other courses of action in individual cases. In all cases, the selected course of
action should be considered by the treating provider in the context of treating
the individual patient. Use of the information is voluntary. ASCO provides
this information on an “as is” basis, and makes no warranty, express or
implied, regarding the information. ASCO speciﬁcally disclaims any war-
ranties of merchantability or ﬁtness for a particular use or purpose. ASCO
assumes no responsibility for any injury or damage to persons or property
arising out of or related to any use of this information or for any errors or
omissions.
Guideline and Conflicts of Interest
The Expert Panel was assembled in accordance with ASCO’s Conﬂict
of Interest Policy Implementation for Clinical Practice Guidelines
(“Policy,” found at http://www.asco.org/rwc) as agreed upon with CAP. All
members of the Expert Panel completed ASCO’s disclosure form, which
requires disclosure of ﬁnancial and other interests, including relationships
with commercial entities that are reasonably likely to experience direct
regulatory or commercial impact as a result of promulgation of the
guideline. Categories for disclosure include employment; leadership; stock
or other ownership; honoraria, consulting or advisory role; speaker’s
bureau; research funding; patents, royalties, other intellectual property;
expert testimony; travel, accommodations, expenses; and other relation-
ships. In accordance with the Policy, the majority of the members of the
Expert Panel did not disclose any relationships constituting a conﬂict
under the Policy.
RECOMMENDATIONS
All recommendations regarding each of the ﬁve clinical
questions are predicated on the assumption that the cases have
been properly ﬁxed, processed, and tested in a laboratory that
follows ASCO/CAP HER2 testing guideline recommendations,
especially those related to IHC and ISH interpretation and
reporting.
In the 2013 Guideline Update, the work-up of cases in the less
common dual-probe ISH categories (groups 2 to 4) addressed in
Clinical Questions 3, 4, and 5 (Fig 3) included only ISH. In this
2018 Focused Update, we recommend that these cases be worked
up by considering both the IHC and the dual-probe ISH results
together. Many publications since the 2013 Guideline Update have
referenced the value of adjudicating ISH results in these un-
common categories using IHC.12,16,19-21 These tests should be
performed on the same tissue sample using sections from the same
block. Ideally, adjacent tissue levels from the same block should be
tested and then reviewed together. If IHC has already been per-
formed, it should be used to guide the selection of the areas to be
counted during ISH such that areas with the strongest protein
expression can be included in ISH scoring. This is common
practice among laboratories performing both testing procedures. If
the ISH laboratory only performs ISH, it is recommended that an
adjacent section in the same block be assessed at a companion IHC
laboratory, and then the slides from both ISH and IHC be reviewed
together to guide the selection of areas to score by ISH. Local
practice considerations will dictate the best procedure to accom-
plish this concomitant review.
Clinical Question 1
What is the most appropriate deﬁnition for IHC 2+ (IHC
equivocal)?
2013 recommendation. IHC 2+ (equivocal) was deﬁned in
Figure 1 of the 2013 HER2 Testing Update as invasive breast cancer
showing “circumferential membrane staining that is incomplete
and/or weak/moderate and within . 10% of tumor cells or
complete and circumferential membrane staining that is intense
and within # 10% of tumor cells.”
Revised 2018 recommendation. In the revised Figure 1, the
revised deﬁnition of IHC 2+ (equivocal) is invasive breast cancer
with “weak to moderate complete membrane staining observed
in . 10% of tumor cells” (Type: evidence based; Evidence quality:
high; Strength of recommendation: strong).
Literature review and analysis. IHC 2+ (equivocal) had been
deﬁned in the 2013 Guideline Update (2013 Fig 1: Algorithm for
evaluation of HER2 protein expression by IHC assay of the
invasive component of a breast cancer specimen) as invasive
breast cancer showing “circumferential membrane staining that
is incomplete and/or weak/moderate and within. 10% of tumor
cells or complete and circumferential membrane staining that
is intense and within # 10% of tumor cells.” However, many
pathologists expressed concern that the terms “circumferential”
and “incomplete” were confusing, could not be reconciled
when used together in the IHC interpretation of HER2 ex-
pression, and could lead to many IHC 1+ (HER2-negative)
tumors being called IHC 2+ (HER2 equivocal) and submitted
for reﬂex testing.
In the same Figure 1 of the 2013 Guideline Update, the
statement “complete and circumferential membrane staining that
is intense and within# 10% of tumor cells” referred to an unusual
pattern that did not need to be speciﬁed in the main portion of the
ﬁgure. This information has now been moved to the footnote of
Figure 1, which will now read as follows: “Unusual staining pat-
terns of HER2 by IHC can be encountered that are not covered by
these deﬁnitions. In practice, these patterns are rare and if en-
countered should be considered IHC 2+ equivocal. As one ex-
ample, some speciﬁc subtypes of breast cancers can show IHC
staining that is moderate to intense but incomplete (basolateral or
lateral) and can be found to be HER2 ampliﬁed.22 Another ex-
ample is circumferential membrane IHC staining that is intense
but within # 10% of tumor cells (heterogeneous but very limited
in extent).”
Consequently, the revised deﬁnition of IHC 2+ (HER2
equivocal) in this 2018 Focused Update (Fig 1) reﬂects a commonly
accepted deﬁnition of invasive breast cancer that now reads “weak
to moderate complete membrane staining observed in . 10% of
tumor cells”.23 During the open comment period, pathologists
requested guidance about the uncommon scenario of cases in
which “intense circumferential membrane staining is observed
in# 10% of tumor cells.” As described in the footnote in Figure 1,
such cases may be considered IHC 2+ equivocal, although addi-
tional samples may reveal different percentages of HER2-positive
staining. These revisions were previously communicated in a 2015
correspondence from the ASCO/CAP HER2 testing Expert Panel
published in JCO.14
Clinical Question 2
Must HER2 testing be repeated on a surgical specimen if
initially negative test on core biopsy?
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2013 recommendation. In Table 2 in the 2013 HER2 testing
Update, it was stated that, on the basis of some criteria (including
a tumor grade 3), “If the initial HER2 test result in a core needle
biopsy specimen of a primary breast cancer is negative, a new
HER2 test must be ordered on the excision specimen . . .”.
Revised 2018 recommendation. In the revised Table 2, it is now
stated that, on the basis of some criteria (including a tumor
grade 3), “If the initial HER2 test result in a core needle biopsy
specimen of a primary breast cancer is negative, a new HER2 test
may be ordered on the excision specimen …” (Type: evidence
based; Evidence quality: high; Strength of recommendation:
strong).
Literature review and analysis. The auxiliary verb “must” was
used in the 2013 Guideline Update (Table 2)1 to indicate that, on
the basis of some criteria (including a tumor grade 3), “If the initial
HER2 test result in a core needle biopsy specimen of a primary
breast cancer is negative, a new HER2 test must be ordered on the
excision specimen . . .”.
The Expert Panel had previously indicated in the Data
Supplement of the 2013 Guideline Update that “smaller datasets
from several investigators seemed to suggest that it might be
possible to identify subsets where the level of suspicion of false
negativity is markedly raised. However, many of these criteria are
consistent with true triple-negative disease, and the (2013) Update
Committee was unsure whether re-testing was indicated for all
such cancers (and) . . . was unable to identify a speciﬁc subgroup
that would beneﬁt frommandatory reﬂex testing if IHC is less than
2+.” Several data sets originally referenced in 2013 showed excellent
concordance for HER2 testing in paired samples (core biopsy
specimen and excision) using IHC as the initial test, such as
a 98.8% concordance observed among 336 patients in the Royal
Marsden experience.24
Rakha et al,17 in their 2015 correspondence to JCO, described
their own institutional experience and that of other groups,
including many previously described in the 2013 Guideline
Update. In its 2015 response14 to the correspondence by Rakha
et al,17 the Expert Panel agreed that, in view of the greater clinical
experience that conﬁrmed the high concordance in HER2 testing
between core and excisional biopsies, it was appropriate to allow
the pathologist and oncologist to exercise clinical judgment and
that grade 3 alone did not sufﬁce as a criterion for mandatory
retesting.
Therefore, in the revised Table 2, the auxiliary verb “must” has
been replaced by “may” to indicate that “If the initial HER2 test
result in a core needle biopsy specimen of a primary breast cancer
is negative, a new HER2 test may be ordered on the excision
specimen…” These changes are the same as those previously
communicated in a 2015 correspondence by the authors of the
2013 Guideline Update and published in JCO.14
Clinical Question 3
Should invasive cancers with aHER2/CEP17 ratio of$ 2.0 but
an average HER2 copy number of , 4.0 signals per cell be con-
sidered ISH positive?
2013 recommendation. Cases in which the HER2/CEP17 ratio
is $ 2.0 with an average HER2 signals per cell of , 4.0 were
considered ISH positive.
Revised 2018 recommendation. If a case has a HER2/CEP17
ratio of $ 2.0 but the average HER2 signals per cell is , 4.0,
a deﬁnitive diagnosis will be rendered based on additional work-
up.
If not already assessed by the institution or laboratory per-
forming the ISH test, IHC testing for HER2 should be performed
using sections from the same tissue sample used for ISH, and the
slides from both ISH and IHC should be reviewed together to guide
the selection of areas to score by ISH (local practice considerations
will dictate the best procedure to accomplish this concomitant
review):
If the IHC result is 3+, diagnosis is HER2 positive.
If the IHC result is 2+, recount ISH by having an additional
observer, blinded to previous ISH results, count at least 20
cells that include the area of invasive cancer with IHC 2+
staining:
• If reviewing the count by the additional observer changes
the result into another ISH category, the result should be
adjudicated per internal procedures to deﬁne the ﬁnal
category.
• If the count remains an average of , 4.0 HER2 signals per
cell and the HER2/CEP17 ratio is$ 2.0, diagnosis is HER2
negative with a comment.
If the IHC result is 0 or 1+, diagnosis is HER2 negative with
a comment.
The Expert Panel recommends the following comment:
Evidence is limited on the efﬁcacy of HER2-targeted therapy in
the small subset of cases with aHER2/CEP17 ratio of$ 2.0 and an
average HER2 copy number of , 4.0 per cell. In the ﬁrst gen-
eration of adjuvant trastuzumab trials, patients in this subgroup
who were randomly assigned to the trastuzumab arm did not
seem to derive an improvement in disease-free or overall survival,
but there were too few such cases to draw deﬁnitive conclusions.
IHC expression for HER2 should be used to complement ISH and
deﬁne HER2 status. If the IHC result is not 3+ positive, it is
recommended that the specimen be considered HER2 negative
because of the low HER2 copy number by ISH and the lack of
protein overexpression.
(Type: evidence based; Evidence quality: intermediate;
Strength of recommendation: strong). An algorithm for Clinical
Question 3 is presented in Figures 3 and 4.
Literature review and analysis. Members of the HER2 testing
Expert Panel in 2013 had expressed concern about describing an
invasive breast cancer as HER2 positive on the basis of a single
HER2 ISH test that showed a HER2/CEP17 ratio of $ 2.0 but an
average HER2 copy number of , 4.0 signals per cell (Fig 3, group
2) and recommended additional testing of such cases. Members of
the 2013 Guideline Update Panel also expressed their view that
using the HER2/CEP17 ratio alone could be misleading in cases
with CEP17 gains or losses and could lead to an under- or
overestimation of HER2 ampliﬁcation. However, the eligibility
criteria for the ﬁrst adjuvant trials of trastuzumab generally fol-
lowed US Food and Drug Administration criteria (IHC 3+ or ISH
ratio $ 2.0 regardless of average HER2 copy number based on
HER2 signals per cell), and the Expert Panel in 2013 ultimately
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opted to consider these rare group 2 patients as having HER2-
positive disease.
Since then, investigators have further reported on the out-
come of patients with a group 2 dual-probe ISH test result. Greater
experience and a more reﬁned collection of test results in the past
few years conﬁrmed that such cases are infrequent (Table 3) and
represented a small number of patients enrolled in the initial
adjuvant trastuzumab trials. Among 4,340 patients (41.5% of
10,468) screened by dual-probe ﬂuorescent ISH (FISH) for trials
BCIRG-005 (HER2 negative trial) and 006 (HER2 positive trial)
and found to have a dual-probe ISH ratio of $ 2.0, only 71 (0.7%
of 10,468) had an average HER2 signals per cell of , 4.0.10
Furthermore, in 35 of these 71 patients who were also tested
later by IHC, only three were IHC 2+ and none were IHC 3+. A
retrospective assessment of potential beneﬁt from trastuzumab in
group 2 patients produced an observed hazard ratio estimate of
slightly . 1.0 (favoring no trastuzumab beneﬁt), but the sample
size was insufﬁcient to statistically rule out a beneﬁt from adjuvant
trastuzumab in this group; nor could it be established statistically
whether group 2 patients not treated with trastuzumab had out-
comes different from patients with HER2-negative disease treated
with just chemotherapy.10 In the HERA trial, group 2 patients were
also uncommon (0.8%) among all patients centrally screened for
eligibility (Table 3), while group 1 patients (ISH ratio $ 2.0 and
average HER2 signals per cell of $ 4.0) represented 55% of all
tested cases (48.7% $ 6.0 and 6.3% $ 4.0 and , 6.0).15 In
summary, the Expert Panel concluded that these group 2 cases
should no longer be considered HER2 positive unless IHC 3+
overexpressed.
Repeat testing of other tissue samples from the patient may
also be appropriate in this setting, and in particularly challenging
cases or if the results are in question, expert consultation may be
appropriate.
Clinical Question 4
Should invasive cancers with an average HER2 copy number
of $ 6.0 signals per cell but a HER2/CEP17 ratio of , 2.0 be
considered ISH positive?
2013 recommendation. Cases in which the HER2/CEP17 ratio
is , 2.0 with an average of $ 6.0 HER2 signals per cell were
considered ISH positive.
Revised 2018 recommendation. If a case has an average of$ 6.0
HER2 signals per cell with a HER2/CEP17 ratio of , 2.0, formerly
diagnosed as ISH positive for HER2, a deﬁnitive diagnosis will be
rendered based on additional work-up.
If not already assessed by the institution or laboratory per-
forming the ISH test, IHC testing for HER2 should be performed
using sections from the same tissue sample used for ISH, and the
slides from both ISH and IHC should be reviewed together to guide
the selection of areas to score by ISH (local practice considerations
will dictate the best procedure to accomplish this concomitant
review):
If the IHC result is 3+, diagnosis is HER2 positive.
If the IHC result is 2+, recount ISH by having an additional
observer, blinded to previous ISH results, count at least 20
cells that include the area of invasion with IHC 2+
staining:
• If reviewing the count by the additional observer
changes the result into another ISH category, the result
should be adjudicated per internal procedures to deﬁne
the ﬁnal category.
• If the HER2/CEP17 ratio remains , 2.0 with $ 6.0 HER2
signals per cell, diagnosis is HER2 positive.
If the IHC result is 0 or 1+, diagnosis is HER2 negative with
a comment.
The Expert Panel recommends the following comment: There
are insufﬁcient data on the efﬁcacy of HER2-targeted therapy
in cases with a HER2 ratio of , 2.0 in the absence of protein
overexpression because such patients were not eligible for the ﬁrst
generation of adjuvant trastuzumab clinical trials. When con-
current IHC results are negative (0 or 1+), it is recommended that
the specimen be considered HER2 negative.
(Type: evidence based; Evidence quality: intermediate;
Strength of recommendation: strong). An algorithm for Clinical
Question 4 is presented in Figures 3 and 5.
Literature review and analysis. Based on available data,
samples with ISH results in this category (ratio , 2.0 and mean
HER2 signals per cell $ 6.0) are uncommon, only representing
between 0.4% and 3.0% of cases sent for dual-probe FISH testing
(Table 3). These ISH cases have increases in both HER2 and
control centromere signals, resulting in ratio results of , 2.0. At
the time of the pivotal HER2 trials, cases with these results were
considered to have duplication of CEP17 (polysomy) and were
most often excluded because they were considered negative
for HER2 gene ampliﬁcation, although Breast Cancer Interna-
tional Research Group (BCIRG-006; Clinicaltrials.gov identiﬁer:
NCT00021255) allowed patients to be enrolled if the HER2 copy
number was $ 10 and central IHC testing was 3+. Subsequent
studies examining multiple regions of chromosome 17 sup-
ported that the majority of cases with these results have HER2
ampliﬁcations that include regions encompassing the centro-
mere rather than true polysomy for the entire chromosome 17
(coampliﬁcation of control and HER2 signals).25-31 Based on
these data, the 2013 Guideline Update clariﬁed that cases with an
average HER2 copy number of $ 6.0 HER2 signals per cell ISH
results (by either single- or dual-probe assays) should be re-
ported as HER2 positive by gene ampliﬁcation. However, it was
acknowledged that data on the clinical response of this group to
HER2 targeted therapies were limited.
Since the 2013 update, additional data have been published
including concurrent IHC results for this ISH category, and they
show that this group can be heterogeneous. Data from a reanalysis
of the HERA trial identiﬁed a small number of cases (21 total)
originally considered negative due to ratios of , 2.0 but with an
average of$ 6.0HER2 signals per cell.15 All of these cases had. 3
mean CEP17 signals per cell, and 75% of them (15 of 20) had
HER2 overexpression by IHC. In a combined study of three major
academic medical centers performing HER2 FISH and IHC,
similar results were seen with 63 cases in this ISH category; 31.7%
were IHC 3+ for HER2 by IHC, 55% were IHC 2+, and 13.7%
were IHC 0 or 1+.16 This study also reported a higher frequency
of Nottingham grade 3 cancers with these ISH results than with
other ISH result categories. Published data from a reference
laboratory at the University of Southern California described 48
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cases with the same ISH characteristics and found that only
8.3% were IHC 3+, while 14.6% were IHC 2+ and 77% were IHC
0 or 1+.12 Additional analysis of these cases identiﬁed a highly
ampliﬁed subgroup (eight total cases) with an average of 12.3HER2
signals per cell that correlated well with HER2 IHC 2+ or 3+ (75%).
This subgroup differed signiﬁcantly from the other subgroup (40
total cases) that had a lower average of 6.8 HER2 signals per cell
and 87.5% IHC negative (0 or 1+) results. Similarly, in the
Breast Cancer International Research Group central testing
clinical trial data, of the limited cases (nine total) with IHC data
and ISH results in this category, one was IHC 3+ positive, one
was IHC 2+, and seven were IHC negative.10 Taken together,
these results suggest that cases in this ISH category form
a heterogeneous group that is best discriminated by the com-
bination of IHC and ISH.
Due to the rarity of cases with these ISH results, there is still
limited clinical evidence regarding beneﬁt from HER2-targeted
therapy. The BCIRG-005 data (no HER2-targeted treatment) in-
dicated a worse disease-free and overall survival for this ISH
category than for cases with both a HER2/CEP17 ratio of , 2.0
and , 4.0 signals per cell (ISH nonampliﬁed).10 However, the few
cases enrolled in the BCIRG-006 adjuvant trastuzumab trial with
these ISH results were insufﬁcient to assess whether there was
beneﬁt from HER2-targeted therapy, and statistical analysis was
not attempted.
Overall, the absence of robust clinical data to guide decisions,
and the variability in IHC data, support the concept that protein
expression results should be used concurrently in this setting to aid
in determining the signiﬁcance of ISH results. In summary, group 3
cases are uncommon and heterogeneous. Based on available data,
the ratio may not be a reliable indicator of the true gene ampli-
ﬁcation status.25-31 Given the evidence that some group 3 cases
have true HER2 ampliﬁcation rather than polysomy for chro-
mosome 17, particularly when the HER2 copy number is high, the
Expert Panel ultimately favored continuing to classify these cases as
HER2 positive unless the concurrent IHC result is clearly negative
(0 or 1+).25-31
Repeat testing of other tissue samples from the patient may
also be appropriate in this setting and, in particularly chal-
lenging cases or if the results are in question, expert consul-
tation may be appropriate and include alternative probes or
other genetic methods.11 However, alternative probes should
not be used as standard practice in view of the absence of
outcome data.
Clinical Question 5
What is the appropriate diagnostic work-up for invasive
cancers with an average HER2 copy number of $ 4.0 but , 6.0
signals per cell and a HER2/CEP17 ratio of , 2.0 and initially
deemed to have an equivocal HER2 ISH test result?
2013 recommendation. Cases in which the HER2/CEP17
ratio is , 2.0 with an average HER2 copy number of $ 4.0
and , 6.0 signals per cell were considered ISH equivocal, and
additional work-up was required (“Must order a reﬂex test
[same specimen using IHC], test with alternative ISH chro-
mosome 17 probe, or order a new test [new specimen if
available, ISH or IHC]”).
Revised 2018 recommendation. If the case has an average
HER2 signals per tumor cell of $ 4.0 and , 6.0 and the HER2/
CEP17 ratio is , 2.0, formerly diagnosed as ISH equivocal for
HER2, a deﬁnitive diagnosis will be rendered based on additional
work-up.
If not already assessed by the institution or laboratory performing
the ISH test, IHC testing for HER2 should be performed using sections
from the same tissue sample used for ISH, and the slides from both ISH
and IHC should be reviewed together to guide the selection of areas to
score by ISH (local practice considerations will dictate the best pro-
cedure to accomplish this concomitant review):
If the IHC result is 3+, diagnosis is HER2 positive.
If the IHC result is 2+, recount ISH by having an additional
observer, blinded to previous ISH results, count at least 20
cells that include the area of invasion with IHC 2+ staining:
• If reviewing the count by the additional observer changes the
result into another ISH category, the result should be adju-
dicated per internal procedures to deﬁne the ﬁnal category.
• If the count remains an average of $ 4.0 and , 6.0 HER2
signals per cell with a HER2/CEP17 ratio of , 2.0, di-
agnosis is HER2 negative with a comment.
If the IHC result is 0 or 1+, diagnosis is HER2 negative with
a comment.
The Expert Panel recommends the following comment: It is
uncertain whether patients with an average of $ 4.0 and , 6.0
HER2 signals per cell and a HER2/CEP17 ratio of , 2.0 beneﬁt
fromHER2 targeted therapy in the absence of protein overexpression
(IHC 3+). If the specimen test result is close to the ISH ratio
threshold for positive, there is a high likelihood that repeat testing
will result in different results by chance alone. Therefore, when IHC
results are not 3+ positive, it is recommended that the sample be
considered HER2 negative without additional testing on the same
specimen).
(Type: evidence based; Evidence quality: intermediate;
Strength of recommendation: strong). An algorithm for Clinical
Question 5 is presented in Figures 3 and 6.
Literature review and discussion. Cases with an average of
$ 4.0 and , 6.0 HER2 signals per cell and a HER2/CEP17 ratio
of, 2.0 were considered equivocal in the 2013 Guideline Update.
This category (group 4 cases) has been reconsidered by the Expert
Panel based on published literature since then, and was discussed
by the representatives of expert laboratories and Expert Panel
members during the open portion of the November 2016 in-
person meeting. In many published studies, the incidence of
equivocal cases has changed since the 2013 update, when more
stringent requirements for ISH interpretation were described.1,4
The number of such cases within a laboratory varies based on the
patient population referred for ISH testing, but it seems to be
approximately 5% of cases (range, 1% to 16%).15,19-21,32-42 The use
of alternative probes to adjudicate these cases has also increased
since 2013.
Data from a central reference laboratory at Mayo Clinic in-
cluded FISH data in a population of patients that is enriched from
those with HER2 IHC 2+ results based on the original IHC testing
performed locally by the referring laboratories (1,922 patients;
85% IHC 2+). Among these cases tested by FISH at Mayo, 14% of
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patients had ISH equivocal results and one half became HER2
positive by ratio when a locally developed and analytically validated
17 p arm probe (D17S122; Mayo Clinic, Rochester, MN) was
combined with the HER2 probe (Abbott Molecular, Abbott Park,
IL) for additional FISH testing. However, clinical information
about beneﬁt from HER2-targeted therapy in such patients is not
available and may not exist because these patients would not have
been eligible for the original pivotal trials.11 The reference labo-
ratory experience reported by Press et al12 involving a different
patient population found 4.6% of patients among 7,526 cases with
equivocal results if using the 2013 criteria; while 89% of these cases
were IHC HER2 0 or 1+, 10% were IHC HER2 2+, and only 0.9%
were IHC HER2 3+ positive. Another academic laboratory ex-
perience that combined results from three laboratories had
a similar frequency of numbers of specimens with equivocal results
(5.2%) among 8,068 patients. Similar clinical characteristics were
observed in patients with an average of $ 4.0 and , 6.0 HER2
signals per cell, regardless of whether the ratio was above or below
2.0, and most of these cases were HER2 negative by IHC and more
likely to be estrogen receptor positive.16
Group 4 cases reported as HER2 equivocal since the 2013
Guideline Update have posed a challenge to oncologists and
patients due to a perceived ambivalence about whether to recom-
mend HER2-targeted therapy. In the absence of an unequivocally
positive or negative test result, multiple testing of the same tissue
sample has been performed frequently, and many laboratories have
relied exclusively on alternative probe testing to resolve cases that are
more difﬁcult. This has often included ISH testing using multiple
chromosome 17 probes at once, many not analytically or clinically
validated. Such indiscriminate testing often results in four or more
ISH ratios being described in a single test report and a ﬁnal des-
ignation of HER2 gene ampliﬁed if just a single ratio is$ 2.0. After
careful consideration of this practice and available data, the Expert
Panel strongly recommends against this as a routine testing strategy.
When the HER2 ratio score is near a decision threshold (positive or
negative), based on random variation in scoring, a subsequent test
may result in a positive or negative score barely crossing the threshold
(on either side). In such cases, repeated ISH testing may therefore
not result in higher conﬁdence in the ﬁnal result.
Clinical correlation with other factors in a particular case
(such as grade and special histologic subtypes) or repeat testing of
other tissue samples from the patient may also be appropriate in
this setting. In particularly challenging cases or if the results are in
question, expert consultation may be appropriate and may include
alternative probes or other genetic methods.11 However, alternative
probes should not be used as standard practice due to limited data
on outcomes for this subset of patients.33
ADDITIONAL RESOURCES
Additional information including data supplements, evidence
tables, and clinical tools and resources can be found at www.asco.
org/breast-cancer-guidelines. Patient information is available there
and at www.cancer.net.
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